Abbott (ABT) Confirms Capacity to Support MCS Devices Demand
Zacks Investment Research | Jun 08, 2021 07:11AM ET
Abbott Laboratories (NYSE:ABT) MDT last week’s decision to discontinue the global distribution and sale of Medtronic’s competitive product HeartWare ventricular assist device (HVAD).
Abbott’s HearMate 3 thus is expected to meet the excess demand that has been created due to the sudden discontinuation of Medtronic’s HVAD.
In addition, Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) as well as training and education for physicians offering Abbott's HeartMate 3 to patients.
Abbott is expected to strengthen its electrophysiology and heart failure business and expand its customer base globally with adequate capacity and supply to meet the growing demand.
More on HeartMate 3/h3
Abbott’s HeartMate 3 heart pump is a small, implantable mechanical circulatory support device for patients with advanced heart failure in need of either short or long-term support awaiting a heart transplant or who are not eligible for heart transplantation.
In a recent study published in the Annals of Thoracic Surgery regarding the risk of adjusted and propensity matched patients supported with the HeartMate 3 demonstrated that actuarial survival rates were 87% at one year and 84% at two years.
More in the News/h3
Per Abbott’s management, life-savings results has been seen in patients treated with mechanical circulatory support devices and ensuring continued access to these devices is important for patients. Abbott is working to make sure that physicians have the support and training as they adopt HeartMate 3 to enhance outcomes for advanced heart failure patients.
Further, left ventricular assist devices (LVADs) remain a vital option for patients with advanced heart failure, either awaiting a heart transplant or not eligible for transplantation which can extend patients’ lives and restore quality of life. Abbott's HeartMate 3 heart pump is available to support physicians and patients globally in markets where the technology has been approved for use.
Recent Developments/h3
In May 2021, Abbott announced a new trial focused on improving treatment for people simultaneously suffering from both atrial fibrillation (AFib) and heart failure. Notably, the trial will make use of Abbott’s technology, including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats. The first-of-its-kind trial intends to offer new insights into more effective treatment for patients with AFib and heart failure -- a complex combination that has historically presented significant challenges to physicians.
In April 2021, Abbott announced the receipt of CE Mark for TriClip Transcatheter Tricuspid Valve Repair System -- the first-of-its-kind minimally invasive tricuspid heart valve repair device to treat tricuspid (TR) regurgitation available in Europe. Notably, the clip-based therapy called TriClip G4 is a non-surgical heart valve repair system designed particularly to treat TR, or a leaky tricuspid valve.
Industry Prospects/h3
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.